PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer

Medical Hypotheses

Volumn 81, Issue 6, 2013, Pages 1151-1154

  Li, Heping ^a   Gao, Hua ^a   Bijukchhe, Sunil Man ^a   Wang, Yunhai ^a   Li, Tao ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; LIGASE; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR ACTIVATED SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; PROTEIN KINASE B; STAT PROTEIN; SUMO PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; EARLY CANCER; EARLY DIAGNOSIS; ENZYME ACTIVITY; HUMAN; HYPOTHESIS; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; PROTEIN INHIBITORS OF ACTIVATED STAT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888438758     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.09.022     Document Type: Article

References (38)

1. Jemal A., Bray F., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Lee B.B., Lee E.J., et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009, 15(19):6185-6191.
3. Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention?. Eur J Cancer Prev 2004, 13(1):71-75.
4. Brenner H., Hoffmeister M., et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010, 102(2):89-95.
5. Mandel J.S., Bond J.H., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N Engl J Med 1993, 328(19):1365-1371.
6. Ahlquist D.A., Wieand H.S., et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993, 269(10):1262-1267.
7. Brenner H., Hoffmeister M., et al. Expected reduction of colorectal cancer incidence within 8years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer 2009, 45(11):2027-2033.
8. Duffy M.J., van Dalen A., et al. Tumour markers in colorectal cancer: european group on tumour markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43(9):1348-1360.
9. Baraniskin A., Nopel-Dunnebacke S., et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer 2013, 132(2):E48-E57.
10. Chung C.D., Liao J., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997, 278(5344):1803-1805.
11. Ueki N., Seki N., et al. Isolation and chromosomal assignment of a human gene encoding protein inhibitor of activated STAT3 (PIAS3). J Hum Genet 1999, 44(3):193-196.
12. Romig H., Fackelmayer F.O., et al. Characterization of SAF-A, a novel nuclear DNA binding protein from HeLa cells with high affinity for nuclear matrix/scaffold attachment DNA elements. EMBO J 1992, 11(9):3431-3440.
13. Jang H.D., Yoon K., et al. PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. J Biol Chem 2004, 279(23):24873-24880.
14. Okubo S., Hara F., et al. NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers. J Biol Chem 2004, 279(30):31455-31461.
15. Rytinki M.M., Kaikkonen S., et al. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 2009, 66(18):3029-3041.
16. Yagil Z., Kay G., et al. A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells. J Immunol 2009, 182(4):2168-2175.
17. Jimenez-Lara A.M., Heine M.J., et al. PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2. FEBS Lett 2002, 526(1-3):142-146.
18. Wang L., Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004, 11(6):1319-1324.
19. Ogata Y., Osaki T., et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 2006, 8(10):817-825.
20. Soloukides A.P., Moutzouris D.A., et al. Renal graft outcome in autosomal dominant medullary cystic kidney disease type 1. J Nephrol 2013, 26(4):793-798.
21. Zhang Q., Raghunath P.N., et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002, 168(1):466-474.
22. Brantley E.C., Nabors L.B., et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008, 14(15):4694-4704.
23. Liu L.M., Yan M.G., et al. PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues. Clin Res Hepatol Gastroenterol 2011, 35(5):393-398.
24. Wu W., Takanashi M., et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer 2013, 108(3):653-661.
25. Granter S.R., Weilbaecher K.N., et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002, 10(1):47-51.
26. Thingnes J., Lavelle T.J., et al. Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection. BMC Syst Biol 2012, 6:11.
27. Levy C., Nechushtan H., et al. A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor. J Biol Chem 2002, 277(3):1962-1966.
28. Yang H., Xu A., et al. Expression of STAT3 and PIAS3 in renal tissues of MRL/lpr mice. Nan Fang Yi Ke Da Xue Xue Bao 2012, 32(6):821-825.
29. Hikata Takaishi, et al. PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. Blood 2009, 113(10):2202-2212.
30. Kluge A., Dabir S., et al. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer 2009, 125(7):1728-1734.
31. Wible B.A., Wang L., et al. Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem 2002, 277(20):17852-17862.
32. Jackson P.K. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 2001, 15(23):3053-3058.
33. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003, 3(11):900-911.
34. Johnson E.S. Protein modification by SUMO. Annu Rev Biochem 2004, 73:355-382.
35. Gross M., Liu B., et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001, 20(29):3880-3887.
36. Dagvadorj A., Tan S.H., et al. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells. Int J Biochem Cell Biol 2010, 42(12):2037-2046.
37. Okumura F., Matsunaga Y., et al. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci 2010, 123(Pt 13):2238-2245.
38. Liu Y., Bridges R., et al. NF-kappaB repression by PIAS3 mediated RelA SUMOylation. PLoS One 2012, 7(5):e37636.